BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22526370)

  • 21. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
    Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of B cell-activating factor in autoimmune pancreatitis.
    Yamanishi H; Kumagi T; Yokota T; Azemoto N; Koizumi M; Kobayashi Y; Abe M; Murakami H; Hiasa Y; Matsuura B; Kawamoto H; Yamamoto K; Onji M
    Pancreas; 2011 Aug; 40(6):840-5. PubMed ID: 21747319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma.
    Filipits M; Drach J; Pohl G; Schuster J; Stranzl T; Ackermann J; Königsberg R; Kaufmann H; Gisslinger H; Huber H; Ludwig H; Pirker R
    Clin Cancer Res; 1999 Sep; 5(9):2426-30. PubMed ID: 10499614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prognostic value of some biochemical and immunologic factors in the management of multiple myeloma].
    Abdulkadyrov KM; Stel'mashenko LV; Bessmel'tsev SS; Lubo-Lesnichenko IF; Sel'tser AV; Rozanova OE; Gubarenko NK; Bubnova LN; Mnuskina MM; Zhuchikhina AA; Blinov MN; Gritskevich NL
    Vopr Onkol; 1998; 44(3):304-9. PubMed ID: 9695777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma.
    Deichmann M; Benner A; Waldmann V; Bock M; Jäckel A; Näher H
    J Exp Clin Cancer Res; 2000 Sep; 19(3):301-7. PubMed ID: 11144523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of telomerase activity in multiple myeloma.
    Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
    Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of Some Proliferation Markers and Some Prognostic Factors in Patients with Multiple Myeloma and their Impact on the Patients' Survival.
    Abdelgawad IA; Radwan NH; Shafik RE; Shokralla HA
    Asian Pac J Cancer Prev; 2016; 17(5):2389-94. PubMed ID: 27268602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris.
    Asashima N; Fujimoto M; Watanabe R; Nakashima H; Yazawa N; Okochi H; Tamaki K
    Br J Dermatol; 2006 Aug; 155(2):330-6. PubMed ID: 16882171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expression and significance of B cell-activating factor of TNF family (BAFF) and B cell lymphoma/leukemia-2 (BCL-2) in multiple myeloma].
    Wang SM; Zhang TL; Jiang YM; Wu HY; Hao LM; Xing XH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):395-8. PubMed ID: 21518495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
    Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
    Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of expression levels of BLyS and its receptors with multiple myeloma.
    Ju S; Wang Y; Ni H; Wang X; Jiang P; Kong X; Zhong R
    Clin Biochem; 2009 Mar; 42(4-5):387-99. PubMed ID: 19028483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.
    Neri P; Kumar S; Fulciniti MT; Vallet S; Chhetri S; Mukherjee S; Tai Y; Chauhan D; Tassone P; Venuta S; Munshi NC; Hideshima T; Anderson KC; Raje N
    Clin Cancer Res; 2007 Oct; 13(19):5903-9. PubMed ID: 17908986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
    Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
    Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection.
    Tarantino G; Marco VD; Petta S; Almasio PL; Barbaria F; Licata A; Bosco GL; Tripodo C; Stefano RD; Craxì A
    J Viral Hepat; 2009 Jun; 16(6):397-405. PubMed ID: 19200135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
    Alexandrakis MG; Passam FH; Kyriakou DS; Christophoridou AV; Perisinakis K; Hatzivasili A; Foudoulakis A; Castanas E
    Am J Hematol; 2004 Feb; 75(2):101-6. PubMed ID: 14755377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
    Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
    Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis.
    Ragheb S; Lisak R; Lewis R; Van Stavern G; Gonzales F; Simon K
    Arch Neurol; 2008 Oct; 65(10):1358-62. PubMed ID: 18852352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.